

Appendix 2: Supplementary figures A-F

Figure A: Funnel plots for cancer and death






Figure B. Time to first other cancer by treatment group*



*Includes all cancers but basal cell and squamous cell skin cancer

Figure C: Plot of mortality grouped by de novo and conversion trial






Figure D: Death-censored renal allograft survival by treatment group




	0	1	2	3	4
# at risk	5876	2576	1161	547	
# at risk(C)	2600	772	610	184	
# at risk(S)	3276	1804	1352	363	

Figure E: Time to first malignancy for patients in conversion trials by treatment group



# at risk	1159	929	708	490
# at risk(C)	441	317	224	157
# at risk(S)	718	612	484	333

Figure F: Risk of outcomes in sirolimus versus control patients – supplementary subgroup analyses*



* These analyses should be interpreted with caution as they are subgroups from trials designed to evaluate sirolimus; patients were not randomized to treatment groups based on induction/no induction or deceased/living donor and may be imbalanced for other factors associated with cancer or death. In addition, 3 trials had missing data on induction therapy and 3 trials had missing data on donor type.